NCT06760260招募中1 期
A Study to Evaluate the Safety and Efficacy of CI-135 CAR-T Cell Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 7
- 试验地点
- 1
- 主要终点
- Dose limited toxicity (DLT)
研究概览
简要总结
This study is a single-arm, open-label, dose-escalating trial to explore the safety, tolerability and pharmacokinetic/pharmacodynamics characteristics of anti human CI-135 (FLT3) CAR-T Injection , and to preliminarily observe the efficacy of the trial drug in patients with relapsed/refractory Acute Myeloid Leukemia.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects must meet all of the following criteria to be enrolled:
- •Subjects volunteer to participate in clinical trails, understand and inform the trials and sign informed consent form, be willing to complete all the trial procedures;
- •Aged from 18 to 70 years (including cut-off value), Male and female;
- •Expected survival > 12 weeks;
- •Previously diagnosed as Acute Myeloid Leukemia by ELN updated criteria (2017) and one of the following indicators that is satisfied:
- •AML patients who have not achieved complete remission (CR) after at least three cycles of standard induction therapy, or
- •AML patients who achieved complete remission after induction therapy but relapsed within one year, or
- •AML patients who achieved complete remission after induction therapy for more than one year but did not achieve remission after one cycle of chemotherapy with the original regimen following relapse, or
- •AML patients who relapsed after transplantation, or
- •AML patients who experienced two or more relapses. Note: For patients meeting conditions a), b), or c) with FLT3 mutations, they must have undergone at least one treatment with a tyrosine kinase inhibitor (TKI) without achieving complete remission or have relapsed after achieving complete remission, except for those who cannot tolerate TKI therapy or have contraindications to TKI treatment.
- •Positive for FLT3 mutation confirmed by leukemia cell genetic testing, or FLT3 expression ≥35%;
- •ECOG performance status score of 1-2;
- •Liver, kidney, heart, and lung functions meeting the following criteria:
- •Glomerular filtration rate (GFR) ≥60 ml/min/1.73 m² or serum creatinine ≤2 times the upper limit of normal (ULN);
- •Serum AST and ALT ≤3 times of ULN, and total bilirubin ≤1.5 times the ULN;
- •Oxygen saturation > 92%;
- •Left ventricular ejection fraction (LVEF) ≥50%, with no pericardial effusion observed on ultrasound, and no clinically significant electrocardiographic abnormalities.
- •Able to understand the study and sign the informed consent form.
排除标准
- •Diagnosed as acute promyelocytic leukemia (APL M3);
- •With any presence of other uncontrolled malignancies (unless evaluated as unlikely to interfere with the safety or efficacy assessment of the trial);
- •Previously treated with CAR-T cells or other genetically modified cellular therapies
- •Displayed history or evidence of significant cardiovascular risks, including any of the following: congestive heart failure, unstable angina, clinically significant arrhythmias (e.g., ventricular fibrillation, ventricular tachycardia), coronary angioplasty within 6 months before administration, implantable cardiac defibrillator, or any clinically relevant comorbidities that pose safety risks or interfere with study assessments, procedures, or completion;
- •Positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) with HBV DNA levels ≥ the detection limit in peripheral blood; positive for hepatitis C virus (HCV) antibody with detectable HCV RNA; positive for human immunodeficiency virus (HIV) antibodies; or positive for syphilis testing;
- •Positive for acute or chronic hepatitis C. Exceptions: acute hepatitis C with complete viral clearance; chronic hepatitis C with a sustained virological response (SVR24) 24 weeks post-treatment confirming undetectable viral load;
- •Having history of arterial or venous thrombosis within 3 months prior to enrollment;
- •Having history of Graft-versus-host disease requiring systemic immunomodulators;
- •Having history of central nervous system diseases or conditions requiring treatment (e.g., uncontrolled seizures);
- •Having uncontrolled active infections;
- •Known allergy to any components of CI-135 CAR-T cell formulation or the lymphodepletion regimen (cyclophosphamide and fludarabine);
- •Currently pregnant or lactating female, or female subjects planning pregnancy within 1 year after cell infusion, or male subjects with partners planning pregnancy within 1 year after infusion;
- •Having other conditions deemed unsuitable for enrollment by the investigator.
研究组 & 干预措施
Experimental: Anti CI-135 (FLT3) CAR-T Injection
Experimental
Single administration: 0.5 * 10^6 CAR-T cells/kg, 1.0 * 10^6 CAR-T cells/kg
干预措施: Human Derived anti-CI135 CAR-T Injection (Drug)
结局指标
主要结局
Dose limited toxicity (DLT)
时间窗: 28 days post infusion
Safety Indicator
次要结局
- Pharmacokinetics parameters - Maximum CAR level in peripheral blood (Cmax)(2 years post infusion)
- Pharmacokinetics parameters -Time to maximum CAR level in peripheral blood (Tmax)(2 years post infusion)
- Pharmacokinetics parameters - 28-day Area under Curve of CAR level in peripheral blood (AUC0-28)(2 years post infusion)
- Pharmacodynamics characteristics - Cytokines Concentrations, cytokines level in peripheral blood(2 years post infusion)
- Overall Response Rate (ORR)(28 days post infusion)
- Progression-free Survival (PFS)(2 years post infusion)
- Overall Survival (OS)(2 years post infusion)
- Duration of Response (DOR)(2 years post infusion)
研究者
研究点 (1)
Loading locations...
相似试验
暂停
1 期
A Clinical Study to Evaluate the Safety and Efficacy of ESO-T01 in Treating Relapsed/Refractory Multiple Myeloma.Multiple MyelomaNCT06691685Union Hospital, Tongji Medical College, Huazhong University of Science and Technology24
招募中
1 期
a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell LeukemiaRelapsed/Refractory Multiple MyelomaRelapsed/Refractory Plasma Cell LeukemiaNCT06718270Shanghai Changzheng Hospital24
Unknown
1 期
A Single Ascending Dose Study Of CY150112 After Single Oral Administration in Healthy Chinese SubjectsSchizophreniaNCT04839926Jiangsu Nhwa Pharmaceutical Co., Ltd.60
招募中
1 期
Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced Solid TumorsSolid Tumor, AdultNCT06088004Suzhou Abogen Biosciences Co., Ltd.218
进行中（未招募）
1 期
KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid TumorsColorectalPancreaticNon-small Cell Lung Cancer (NSCLC)NCT06767046Corregene Biotechnology Co., Ltd8